









INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07C 271/64, C07D 311/84, 335/14, 263/48, 271/113, 271/07, 413/12, 213/30, 333/16, C07C 333/10, C07D 213/61, C07C 233/90, 233/91, C07D 295/088, A61K 31/325, 31/352, 31/382, 31/421, 31/422, 31/4245, A61P 25/00</p>	A1	<p>(11) International Publication Number: WO 00/63166</p> <p>(43) International Publication Date: 26 October 2000 (26.10.00)</p>
<p>(21) International Application Number: PCT/EP00/03556</p> <p>(22) International Filing Date: 19 April 2000 (19.04.00)</p> <p>(30) Priority Data: 99107843.7 20 April 1999 (20.04.99) EP</p> <p>(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH).</p> <p>(72) Inventors: BLEICHER, Konrad; Aschenbrennerstrasse 18, D-79110 Freiburg (DE). MUTEL, Vincent; 15, place des Maréchaux, F-68100 Mulhouse (FR). VIEIRA, Eric; Burgfelderstrasse 63, CH-4123 Allschwil (CH). WICHMANN, Jürgen; Im Wolfischbühl 32, D-79585 Steinen (DE). WOLTERING, Thomas, Johannes; Riedlistrasse 13, D-79576 Weil am Rhein (DE).</p> <p>(74) Agent: POPPE, Regina; Grenzacherstrasse 124, CH-4070 Basle (CH).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(A)</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 20px;"> <div style="text-align: center;">  <p>(a)</p> </div> <div style="text-align: center;">  <p>(b)</p> </div> <div style="text-align: center;">  <p>(c)</p> </div> <div style="text-align: center;">  <p>(d)</p> </div> </div>		
<p>(57) Abstract</p> <p>The present invention relates to compounds of formula (I) wherein X signifies O, S or two hydrogen atoms not forming a bridge; A¹/A² signify, independently from each other, phenyl or a 6-membered heterocycle containing 1 or 2 nitrogen atoms; B is a group of formula (A), wherein Y signifies -O-, -S- or a bond; Z signifies -O- or -S-; or B is a 5-membered heterocyclic group of formulas (a, b, c or d). These compounds may be used as metabotropic glutamate receptor ligands in the control or prevention of acute and/or chronic neurological disorders.</p>		


FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		


CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS

The present invention is concerned with carbamic acid ester derivatives of the general formula



wherein

- 5 R¹ signifies hydrogen or lower alkyl;
 R², R^{2'} signify, independently from each other, hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;
 X signifies O, S or two hydrogen atoms not forming a bridge;
 A¹/A² signify, independently from each other, phenyl or a 6-membered heterocycle
 10 containing 1 or 2 nitrogen atoms;
 B is a group of formula




wherein

- 15 R³ signifies lower alkyl, lower alkenyl, lower alkynyl, benzyl, lower alkyl-cycloalkyl, lower alkyl-cyano, lower alkyl-pyridinyl, lower alkyl-lower alkoxy-phenyl, lower alkyl-phenyl, which is optionally substituted by lower alkoxy, or phenyl, which is optionally substituted by lower alkoxy, or lower alkyl-thienyl, cycloalkyl, lower alkyl-trifluoromethyl or lower alkyl-morpholinyl;
 Y signifies -O-, -S- or a bond;

Z signifies -O- or -S-;

or B is a 5-membered heterocyclic group of formulas





wherein


- 5 R^4 and R^5 signifies hydrogen, lower alkyl, lower alkoxy, cyclohexyl, lower alkyl-cyclohexyl or trifluoromethyl, with the proviso that at least one of R^4 or R^5 has to be hydrogen;

as well as with their pharmaceutically acceptable salts.


In particular, the invention relates to compounds of the following structures:




- 3 -



or



or



5

wherein the definition of substituents is given above.

These compounds and their salts are novel and are distinguished by valuable therapeutic properties.

It has surprisingly been found that the compounds of general formula I are
10 metabotropic glutamate receptor antagonists and/or agonists.

In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor.

L-glutamic acid, the most commonly occurring neurotransmitter in the CNS, plays a critical role in a large number of physiological processes. The glutamate-dependent
15 stimulus receptors are divided into two main groups. The first main group forms ligand-controlled ion channels. The metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G-protein-coupled receptors.

At present, eight different members of these mGluRs' are known and of these some

- 4 -

even have sub-types. On the basis of structural parameters, the different second messenger signalling pathways and the different affinity to low-molecular weight chemical compounds, these eight receptors can be sub-divided into three sub-groups:


- mGluR1 and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II
 5 and mGluR4, mGluR6, mGluR7 and mGluR8 belong to group III.

Ligands of metabotropic glutamate receptors belonging to the first group can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as chronic and acute pain.

- 10 Other treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Huntington's chorea, amyotrophic lateral sclerosis (ALS),
 15 parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, opiate addiction, anxiety, vomiting, dyskinesia and depression.

- Objects of the present invention are compounds of formula I and their
 20 pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.

- 25 Preferred compounds of formula I in the scope of the present invention are those, in which A signifies phenyl, X signifies 2 hydrogen atoms not forming a bridge and B signifies the group




wherein Z is O and R³ and Y are described above

- 5 -

The following are examples of such compounds:

diphenylacetyl-carbamic acid butyl ester,
diphenylacetyl-carbamic acid ethyl ester or
diphenylacetyl-carbamic acid pent-4-ynyl ester.

- 5 Compounds of formula I, wherein A signifies phenyl, X signifies -O- or -S- and B signifies the group




are further preferred, wherein Z is O and R^3 and Y are described above

Examples of such compounds are:

- 10 (9H-xanthene-9-carbonyl)-carbamic acid ethyl ester,
(9H-xanthene-9-carbonyl)-carbamic acid butyl ester or
(9H-thioxanthene-9-carbonyl)-carbamic acid butyl ester.

Preferred compounds of formula I in the scope of the present invention are those, in which
A signifies phenyl, X signifies 2 hydrogen atoms not forming a bridge and B signifies a

- 15 heterocyclic group of the formulas




wherein R^4 and R^5 have the significances given above.

Examples of such compounds are:

- N-(5-ethyl-oxazol-2-yl)-2,2-diphenyl-acetamide,
20 N-(5-methyl-oxazol-2-yl)-2,2-diphenyl-acetamide,
2,2-diphenyl-N-(5-propyl-[1,3,4]oxadiazol-2-yl)-acetamide,
N-[5-(2-methoxy-ethyl)-[1,3,4]oxadiazol-2-yl]-2,2-diphenyl-acetamide,
N-(3-methyl-[1,2,4]oxadiazol-5-yl)-2,2-diphenyl-acetamide,
N-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-2,2-diphenyl-acetamide or
25 N-(5-methyl-[1,2,4]oxadiazol-3-yl)-2,2-diphenyl-acetamide

- 6 -

Preferred are further compounds of formula I, in which A signifies phenyl,
X signifies -O- or -S-; and B signifies a heterocyclic group of the formulas



for example the following compounds:

- 5 9H-xanthene-9-carboxylic acid oxazol-2-yl-amide,
- 9H-xanthene-9-carboxylic acid (5-propyl-[1,3,4]oxadiazol-2-yl)-amide,
- 9H-xanthene-9-carboxylic acid (5-ethyl-oxazol-2-yl)-amide,
- 9H-xanthene-9-carboxylic acid (5-methyl-oxazol-2-yl)-amide,
- 9H-xanthene-9-carboxylic acid (5-propyl-oxazol-2-yl)-amide,
- 10 9H-xanthene-9-carboxylic acid (5-ethyl-[1,3,4]oxadiazol-2-yl)-amide,
- 9H-xanthene-9-carboxylic acid (5-cyclopropylmethyl-[1,3,4]oxadiazol-2-yl)-amide,
- 9H-xanthene-9-carboxylic acid (4-methyl-oxazol-2-yl)-amide,
- 9H-xanthene-9-carboxylic acid (3-methyl-[1,2,4]oxadiazol-5-yl)-amide,
- 9H-Xanthene-9-carboxylic acid (5-trifluoromethyl-[1,3,4]oxadiazol-2-yl)-amide,
- 15 9H-Xanthene-9-carboxylic acid (5-methoxymethyl-[1,3,4]oxadiazol-2-yl)-amide,
- 9H-xanthene-9-carboxylic acid (3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-amide or
- 9H-xanthene-9-carboxylic acid (5-methyl-[1,2,4]oxadiazol-3-yl)-amide.

The invention embraces all stereoisomeric forms in addition to the racemates.

- 20 The term "lower alkyl" used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1 – 7 carbon atoms, preferably with 1 – 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl and the like.


The term "lower alkoxy" denotes a lower alkyl residue in the sense of the foregoing definition bonded via an oxygen atom.

- 25 The term "halogen" embraces fluorine, chlorine, bromine and iodine.


The compounds of general formula I and their pharmaceutically acceptable salts can be manufactured by processes, which comprises

- 7 -

a) reacting a compound of the formula




with a compound of the formula




5

to a compound of formula



wherein the substituents have the significances given above, or


b) reacting a compound of formula




10

- 8 -

with a compound of the formula




to a compound of formula




- 5 in which G is a suitable leaving group, such as Cl, Br or acyloxy, or a carbonyl chloride equivalent such as a carbonyl-pyrazolide, carbonyl imidazole, carbonyl benzotriazole, carbonyloxysuccinimide, or activated esters such as p-nitrophenylester, pentachlorophenylester and the like, and the other substituents have the significances given above,

- 10 c) or reacting a compound of formula




with a compound of the formula




to a compound of formula

- 9 -




or

d) reacting a compound of formula




5

with a compound of the formula




to a compound of formula




10 wherein the substituents have the significances set forth above, or

- 10 -


e) reacting a compound of formula




with a heterocyclic compound of formula



5 to give a compound of formula



wherein B is a 5-membered heterocycle of the formulas



and wherein the remaining substituents have the significances given above,

10 and, if desired,

converting a functional group in a compound of formula I into another functional group
and, if desired,

converting a compound of formula I into a pharmaceutically acceptable salt.

In accordance with process variant a) to a compound of formula III, for example an alcohol (1-butanol, benzyl alcohol, allyl alcohol, isopropyl-alcohol) in dichloromethane is added a compound of formula II, for example diphenylacetyl isocyanate and the mixture is stirred at room temperature.

- 5 Compounds of formula IA may be prepared in accordance with process variant b). A compound of formula V, for example a corresponding urethane or carbamic acid alkyl ester, is reacting with a compound of formula IV, for example with 9H-xanthene-9-carbonyl chloride or bromide, or with an acyloxy derivative of formula IV, or with a carbonyl chloride equivalent of formula IV, which compounds contain a carbonyl-
- 10 pyrazolide group, a carbonyl imidazole group, a carbonyl benzotriazole group, a carbonyloxysuccinimide group or an activated ester such as p-nitrophenylester, pentachlorophenylester and the like. This reaction is carried out in a solvent, such as pyridine, at room temperature by methods known in the art.
- Furthermore, compounds of formula IA-1 and IA may be prepared in accordance with
- 15 process variant c) and d), wherein a compound of formula VI is reacting with a compound of formula VII or VIII. This reaction is carried out similar to those, described for process variant b).

Compounds of formula IB may be prepared by a reaction of a heterocyclic compound of formula IX with a compound of formula IV in the presence of N,N-dimethylamino

20 pyridine at a temperature of 0°C. The preferred solvent is methylene chloride.

The pharmaceutically acceptable salts can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt. Inorganic or organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid,


25 fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I. Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation or

30 pharmaceutically acceptable salts of acidic compounds.

Scheme 1 gives an overview of the manufacture of the compounds of formula IA. The manufacture of representative compounds of formula I is described in detail in examples 1 - 30, 32 and 34 - 43. Scheme 2 describes the process of manufacture of compounds of formula IB, which process is described in more detail in examples 31, 33


35 and 44 - 69.

Scheme 1




The substituents have the significances given earlier.

Scheme 2



wherein B is a 5-membered heterocyclic compound of formulas



and the remaining definitions of substituents are given above.

- 5 The starting materials used in schemes 1 and 2 are known compounds or may be prepared by methods known per se.

The compounds of formula I and their pharmaceutically acceptable salts are, as already mentioned above, metabotropic glutamate receptor agonists and/or antagonists and can be used for the treatment or prevention of acute and/or chronic neurological disorders, such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits, as well as acute and chronic pain. Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Alzheimer's disease, Huntington's

10

chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia
5 and depression.

The compounds of the present invention are group I mGlu receptor agonists and/or antagonists. For example, it has been shown that the compounds of examples 1 - 22 and 30 - 69 show agonistic activities and those of examples 23 - 29 are antagonists. The compounds show activities, as measured in the assay described below, of 50 μ M or less,
10 typically 1 μ M or less, and ideally of 0.5 μ M or less.

In the table below are shown some specific activity-data:

Example No.	agonist/antagonist	IC ₅₀ (μ M)
10	agonist	0.22
32	agonist	0.14
65	agonist	0.4
23	antagonist	6.31
24	antagonist	2.79
25	antagonist	1.38

Test description

cDNA encoding rat mGlu 1a receptor obtained from Prof. S. Nakanishi (Kyoto, Japan) was transiently transfected into EBNA cells using a procedure described by Schlaefer et al, New Dev. New Appl. Anim. Cell Techn., Proc. ESACT Meet., 15, (1998), 105-112 and 117-120. [Ca²⁺]_i measurements were performed on mGlu 1a transfected EBNA cells after incubation of the cells with Fluo-3 AM (0.5 μ M final concentration) for 1 hour at 37°C followed by 4 washes with assay buffer (DMEM supplemented with Hank's salt and 20 mM HEPES). [Ca²⁺]_i measurements were done using a fluorometric imaging
20 plate reader (FLIPR, Molecular Devices Corporation, La Jolla, CA, USA). When

compounds were evaluated as antagonists they were tested against 10 μ M glutamate as agonist.

The inhibition (antagonists) or activation (agonists) curves were fitted with a four parameter logistic equation giving EC_{50} , and Hill coefficient using the iterative non linear
5 curve fitting software Origin (Microcal Software Inc., Northampton, MA, USA).

The compounds of formula I and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the admini-
10 stration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid
15 or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are,
20 for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

25 In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

As mentioned earlier, medicaments containing a compound of formula I or a
30 pharmaceutically acceptable salt thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable

- 16 -

substances into a galenical dosage form together with one or more therapeutically inert carriers.

The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral
5 administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day.

Finally, as mentioned earlier, the use of compounds of formula I and of
10 pharmaceutically acceptable salts thereof for the production of medicaments, especially for the control or prevention of acute and/or chronic neurological disorders of the aforementioned kind, is also an object of the invention.

Example 1Diphenylacetyl-carbamic acid butyl ester

To a stirred solution of 1-butanol (0.32 ml, 3.49 mmol) in dichloromethane (4 ml) was added a solution of diphenylacetyl isocyanate (2.33 ml, 0.5M in CH₂Cl₂, 1.16 mmol) and the mixture was stirred at RT for 1 h. Removal of the solvent in vacuum left a yellow oil, which was purified by column chromatography on silica gel (ethyl acetate/hexane 1:2) to give the title compound (0.3 g, 83%) as a light yellow solid, m.p. 82-84 °C and MS: m/e = 334 (M+Na⁺).

Example 2Diphenylacetyl-carbamic acid benzyl ester

The title compound, white solid, m.p. 100-101 °C and MS: m/e = 345 (M⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and benzyl alcohol.

Example 3Diphenylacetyl-carbamic acid allyl ester

The title compound, white solid, m.p. 118-120 °C and MS: m/e = 295 (M⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and allyl alcohol.

Example 4Diphenylacetyl-carbamic acid isopropyl ester

The title compound, white solid, m.p. 122-124 °C and MS: m/e = 297 (M⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and isopropyl alcohol.

Example 5Diphenylacetyl-carbamic acid tert.-butyl ester

The title compound, light yellow solid, m.p. 160-162 °C and MS: m/e = 334 (M+Na⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and tert.-butyl alcohol.

Example 6(9H-Xanthene-9-carbonyl)-carbamic acid ethyl ester

To a stirred solution of urethane (0.82 g, 9.21 mmol) and DMAP (0.05 g, 0.41 mmol) in pyridine (10 ml) was added at 0°C 9H-xanthene-9-carbonyl chloride (1.50 g, 6.13 mmol). Stirring was continued at RT for 17 h, the reaction mixture was evaporated and water (50 ml)/sat. NaHCO₃ solution (20 ml) was added. The solid was filtered off and crystallized from water and afterwards from EtOH/hexane to give the product (1.22 g, 67%) as a white solid, m.p. 228°C (dec.) and MS: m/e = 298.2 (M+H⁺).

Example 7(RS)-(2-Bromo-9H-xanthene-9-carbonyl)-carbamic acid ethyl ester

The title compound, light brown solid, m.p. 203°C and MS: m/e = 375 (M^+) was prepared in accordance with the general method of example 6 from urethane and 2-bromo-9H-xanthene-9-carbonyl chloride.

Example 8(9H-Xanthene-9-carbonyl)-carbamic acid butyl ester

The title compound, white solid, m.p. = 180-183°C, MS: m/e = 325.4 ($M+H^+$) was prepared in accordance with the general method of example 6 from 9H-xanthene-9-carbonyl chloride and carbamic acid butyl ester.

Example 9Diphenylacetyl-carbamic acid ethyl ester

The title compound, white solid, m.p. 133°C and MS: m/e = 284.2 ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenyl-acetyl isocyanate and ethanol.

Example 10Diphenylacetyl-carbamic acid cyclopropylmethyl ester

The title compound, white solid, m.p. = 108°C, MS: m/e = 309.4 ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and cyclopropyl-methanol.

Example 11Diphenylacetyl-carbamic acid pent-4-ynyl ester

The title compound, white solid, m.p. 109°C and MS: m/e = 321.4 ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and pent-4-yn-1-ol.

Example 12Diphenylacetyl-carbamic acid 2-cyano-ethyl ester

The title compound, white solid, m.p. 113°C and MS: m/e = 308.3 ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and 3-hydroxy-propionitrile.

Example 13Diphenylacetyl-carbamic acid 3-pyridin-4-yl-propyl ester

The title compound, brown solid, m.p. 147-50°C and MS: m/e = 374.4 ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and 3-pyridin-4-yl-propan-1-ol.

Example 14Diphenylacetyl-carbamic acid 3-benzyloxy-propyl ester

The title compound, colorless oil, MS: $m/e = 403.5$ ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and 3-benzyloxy-
5 propan-1-ol.

Example 15Diphenylacetyl-carbamic acid 2-(3,4-dimethoxy-phenyl) ethyl ester

The title compound, white solid, m.p. 144°C and MS: $m/e = 419.5$ ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and 2-
10 (3,4-dimethoxy-phenyl)-ethanol.

Example 16Diphenylacetyl-carbamic acid (RS)-2-phenyl-propyl ester

The title compound, white solid, m.p. 131°C and MS: $m/e = 373.5$ ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and
15 (RS)-2-phenyl-propan-1-ol.

Example 17Diphenylacetyl-carbamic acid thien-2-yl methyl ester

The title compound, white solid, m.p. 116°C and MS: $m/e = 351.4$ ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and
20 thien-2-yl-methanol.

Example 18Diphenylacetyl-carbamic acid cyclopentyl ester

The title compound, white solid, m.p. $120-123^\circ\text{C}$ and MS: $m/e = 323.4$ (MH^+) was prepared in accordance with the general method of example 1 from diphenylacetyl
25 isocyanate and cyclopentanol.

Example 19Diphenylacetyl-carbamic acid cyclohexyl ester

The title compound, white solid, m.p. $117-119^\circ\text{C}$ and MS: $m/e = 337.4$ ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl
30 isocyanate and cyclohexanol.

Example 20Diphenylacetyl-carbamic acid 4-phenyl-butyl ester

The title compound, light yellow solid, m.p. $= 118^\circ\text{C}$ and MS: $m/e = 387.5$ ($M+H^+$) was prepared in accordance with the general method of example 1 from diphenylacetyl
35 isocyanate and 4-phenyl-butan-1-ol.

Example 21Diphenylacetyl-carbamic acid 3,5-dimethoxy-phenyl ester

The title compound, white solid, m.p. = 150-152°C and MS: m/e = 391.4 (M+H⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and 3,5-dimethoxy-phenol.

Example 22Diphenylacetyl-carbamic acid 2,2,2-trifluoro-ethyl ester

The title compound, white solid, m.p. = 125-127°C and MS: m/e = 337.3 (M+H⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and 2,2,2 trifluoro-ethanol.

Example 23(2,2-Diphenyl-propionyl)-carbamic acid methyl ester

The title compound, colorless gum, MS: m/e = 297.4 (M+H⁺) was prepared in accordance with the general method of example 1 from crude 2,2-diphenylpropionyl isocyanate and ethanol.

Example 24(2,2-Diphenyl-propionyl)-carbamic acid allyl ester

The title compound, white solid, m.p. = 89°C and MS: m/e = 309.4 (M+H⁺) was prepared in accordance with the general method of example 1 from 2,2-diphenylpropionyl isocyanate and prop-2-en-1-ol.

Example 25(2,2-Diphenyl-propionyl)-carbamic acid butyl ester

The title compound, white solid, m.p. = 83°C and MS: m/e = 325.4 (M+H⁺) was prepared in accordance with the general method of example 1 from 2,2-diphenylpropionyl isocyanate and butan-1-ol.

Example 26(2,2-Diphenyl-propionyl)-carbamic acid cyclopropyl methyl ester

The title compound, white solid, m.p. = 125°C and MS: m/e = 323.4 (M+H⁺) was prepared in accordance with the general method of example 1 from 2,2-diphenylpropionyl isocyanate and cyclopropyl-methanol.

Example 27(2,2-Diphenyl-propionyl)-carbamic acid cyclohexyl ester

The title compound, white solid, m.p. = 126°C and MS: m/e = 351.4 (M+H⁺) was prepared in accordance with the general method of example 1 from 2,2-diphenylpropionyl isocyanate and cyclohexanol.

Example 28(2,2-Diphenyl-propionyl)-carbamic acid 4-phenyl-butyl ester

The title compound, yellow oil, MS: $m/e = 401.5$ ($M+H^+$) was prepared in accordance with the general method of example 1 from 2,2-diphenylpropionyl isocyanate and 4-phenyl-
5 butan-1-ol.

Example 29(2,2-Diphenyl-propionyl)-carbamic acid 2,2,2-trifluoro-ethyl ester

The title compound, white solid, m.p. = 143-145°C, MS: $m/e = 351.3$ ($M+H^+$) was prepared in accordance with the general method of example 1 from 2,2-diphenylpropionyl
10 isocyanate and 2,2,2-trifluoro-ethanol.

Example 30(9H-Thioxanthene-9-carbonyl)-carbamic acid ethyl ester

The title compound, white solid, m.p. = 179-182°C, MS: $m/e = 314.2$ ($M+H^+$) was prepared in accordance with the general method of example 6 from 9H-thioxanthene-9-
15 carbonyl chloride [U.S. Pat. 3,284,449] and urethane.

Example 319H-Thioxanthene-9-carboxylic acid oxazol-2-ylamide

To a stirred solution of (0.048 g, 0.575 mmol) 2-amino-oxazole [Cockerill & al., Synthesis 591(1976)], and DMAP (0.003 g, 0.03 mmol) in pyridine (2 ml) was added at 0°C (0.100 g,
20 0.384 mmol) 9H-thioxanthene-9-carbonyl chloride. Stirring was continued at RT for 16 h, the reaction mixture was evaporated and water (5 ml)/sat. NaHCO_3 solution (2 ml) was added. The solid was filtered off, dissolved in dichloromethane, dried (MgSO_4), and concentrated in vacuo. The crude material was purified by column chromatography on silica gel (methylene chloride/ methanol 40:1) to give the product (0.022 g, 18%) as a white
25 solid, m.p. 188-191°C and MS: $m/e = 309.1$ ($M+H^+$).

Example 32(9H-Thioxanthene-9-carbonyl)-carbamic acid butyl ester

The title compound, white solid, m.p. = 151-154°C, MS: $m/e = 342.2$ ($M+H^+$) was prepared in accordance with the general method of example 6 from 9H-thioxanthene-9-
30 carbonyl chloride and carbamic acid butyl ester.

Example 339H-Xanthene-9-carboxylic acid oxazol-2-yl-amide

The title compound, white solid, m.p. = 232-235°C, MS: $m/e = 292$ (M^+) was prepared in accordance with the general method of example 31 from 9H-xanthene-9-carbonyl chloride
35 and 2-amino-oxazole.

Example 34Diphenylacetyl-carbamic acid 2-morpholin-4-yl-ethyl ester

The title compound, white solid, m.p. = 135-137°C and MS: m/e = 369.3 (M+H⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and 2-morpholin-4-yl-ethanol.

Example 35Diphenylacetyl-thiocarbamic acid S-butyl ester

The title compound, white solid, m.p. = 99°C and MS: m/e = 327 (M⁺) was prepared in accordance with the general method of example 1 from diphenylacetyl isocyanate and butanethiol.

Example 36[(3-Chloro-5-trifluoromethyl-pyridin-2-yl)-m-tolyl-acetyl]-carbamic acid ethyl ester

97 µl (95 mg, 0.80 mmol) Diethylcarbonate and 38 µl (30 mg, 0.50 mmol) isopropanol were dissolved in 2 ml of absolute THF. The solution was cooled to 0°C and 29 mg (0.67 mmol) sodium hydride dispersion (55% in mineral oil) was added. Then 164 mg (0.50 mmol) 3-chloro-5-trifluoromethyl-2-pyridyl-3-methylphenylacetamide in portions at 0°C. After stirring for 1h at 0°C, the reaction was allowed to warm up to room temperature and stirred overnight. Workup in the usual manner with ammonium chloride solution and ethyl acetate yielded a yellow oil which was purified by flash chromatography on silicagel using a 5:1 mixture of hexane and ethyl acetate as eluant. One obtains 14.1mg (0.035 mmol, 7%) of [(3-chloro-5-trifluoromethyl-pyridin-2-yl)-m-tolyl-acetyl]-carbamic acid ethyl ester as a white solid, m.p. = 146-147°C, MS: m/e = 401.3 (M+H).

Example 379H-Xanthene-9-carbonyl)-carbamic acid cyclopropylmethyl ester

The title compound, white solid, m.p. = 183-185°C, MS: m/e = 323 (M⁺) was prepared in accordance with the general method of example 36 from 9H-xanthene-9-carbonyl chloride and carbamic acid cyclopropylmethyl ester.

Example 38(4-Trifluoromethyl-9H-xanthene-9-carbonyl)-carbamic acid ethyl ester

The title compound, white solid, m.p. = 196-198°C, MS: m/e = 365 (M⁺) was prepared in accordance with the general method of example 36 from 4-trifluoromethyl-9H-xanthene-9-carbonyl chloride and carbamic acid ethyl ester.

Example 39Cyclopropanecarboxylic acid diphenylacetyl-amide

- 23 -

To a stirred and cooled (0°C) solution of 2,2-diphenylacetamide (500 mg, 2.36 mmol) in THF (20 ml) was added sodium hydride (95 mg, 2.36 mmol; 60%) and the mixture was stirred at RT for 0.5 h. Then cyclopropanecarboxylic acid chloride (247 mg, 2.36 mmol) dissolved in THF (5 ml) was added dropwise at RT and the solution was stirred at RT for 5 20 h. The reaction mixture was poured into sat. NaHCO₃ solution (50 ml) and extracted with ethyl acetate (2 x 70 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO₄) and evaporated. Further purification by column chromatography (toluene/ethyl acetate 19:1) yielded the product which was recrystallized from ethyl acetate/hexane to give a white solid (133 mg, 20%), m.p. 178°C and MS: m/e = 279 (M⁺).

10

Example 409H-Xanthene-9-carboxylic acid butyryl-amide

The title compound, white solid, m.p. 222°C and MS: m/e = 295 (M⁺) was prepared in accordance with the general method of example 39 from 9H-xanthene-9-carboxylic acid amide and propanecarboxylic acid chloride.

15

Example 41N-Diphenylacetyl-butylamide

The title compound, white solid, m.p. 205°C and MS: m/e = 281 (M⁺) was prepared in accordance with the general method of example 39 from 2,2-diphenylacetamide and propanecarboxylic acid chloride.

20

Example 42Pentanecarboxylic acid diphenylacetyl-amide

The title compound, white solid, m.p. 87°C and MS: m/e = 309 (M⁺) was prepared in accordance with the general method of example 39 from 2,2-diphenylacetamide and pentanecarboxylic acid chloride.

25

Example 43Pentanoic acid diphenylacetyl-amide

The title compound, white solid, m.p. 83°C and MS: m/e = 296.3 (M+H⁺) was prepared in accordance with the general method of example 39 from 2,2-diphenylacetamide and butanecarboxylic acid chloride.

30

Example 449H-Xanthene-9-carboxylic acid (5-propyl-[1,3,4]oxadiazol-2-yl)-amide

44a) To a solution of 76 mg (0.60 mmol, 1.2 equiv.) 5-propyl-[1,3,4]oxadiazol-2-ylamine and 6 mg (0.05 mmol, 0.1 equiv.) of N,N-dimethylamino pyridine in 2 ml of dry pyridine was added a solution of 122 mg (0.5 mmol) 9-xanthene-carboxylic acid chloride in 1.22 ml of methylene chloride dropwise at 0°C. The mixture was stirred 3-4 h at 0°C and then at
5 room temperature overnight. The mixture was poured into a well stirred mixture of 50 ml of ethyl acetate and 50 ml of water. The organic phase was separated. The aqueous phase was extracted twice with 25 ml of ethyl acetate. The combined organic phases were washed twice with 25 ml of water, and concentrated. The residue was taken up in c.a. 25 ml of ethyl acetate and evaporated to dryness. The crude product (167 mg, light yellow solid) yielded,
10 after recrystallisation from ethanol 62 mg (0.185 mmol, 37%) of 9H-xanthene-9-carboxylic acid (5-propyl-[1,3,4]oxadiazol-2-yl)-amide as white crystals, m.p. 215-216°C and MS: m/e = 335 (M^+).

44b) The 5-propyl-[1,3,4]oxadiazol-2-ylamine used in the above reaction was obtained as follows:

15 To a solution of 5.0 g (47.0 mmol) cyanogen bromide in 50 ml of methanol was added dropwise over a period of 30 min a solution of 4.80 g (47.0 mmol) butyric acid hydrazide in 50 ml of methanol. The mixture was then refluxed for 15 min, and then concentrated in vacuo till crystallisation began. The crystals (9 g) were filtered off, taken up in 60 ml of ethanol. Then 5 g of finely powdered potassium carbonate were added and the suspension
20 was stirred for 5 min at room temperature. The resulting orange suspension was filtered, and the filtrate was concentrated in vacuo. The resulting orange powder (5.5 g) was purified by flash chromatography on silicagel with a 80:10:1 mixture of methylene chloride/methanol/28% ammonia as eluent to yield 3.95 g (31.1 mmol, 66%) of 5-propyl-[1,3,4]oxadiazol-2-ylamine as white crystals, MS: m/e = 127 (M^+).

25

Example 45

2,2-Diphenyl-N-(5-propyl-[1,3,4]oxadiazol-2-yl)-acetamide.

The title compound, viscous oil and MS: m/e = 322.4 ($M+H^+$) was prepared in accordance with the general method of example 44a from 5-propyl-[1,3,4]oxadiazol-2-ylamine and 2,2-diphenylacetic acid chloride.

30

Example 46

9H-Xanthene-9-carboxylic acid [1,3,4]oxadiazol-2-ylamide.

The title compound, white solid, m.p. 239-240°C and MS: m/e = 293 (M^+) was prepared in accordance with the general method of example 44a from [1,3,4]oxadiazol-2-ylamine and 9-xanthene-carboxylic acid chloride.

The [1,3,4]oxadiazol-2-ylamine, white solid, MS: $m/e = 85$ (M^+) used in the above reaction was prepared in accordance with the general method of example 44b from formic acid hydrazide and cyanogen bromide.

Example 47

5 N-[1,3,4]Oxadiazol-2-yl-2,2-diphenyl-acetamide.

The title compound, light yellow solid, m.p. 131-132°C and MS: $m/e = 279.2$ (M^+) was prepared in accordance with the general method of example 44a from [1,3,4]oxadiazol-2-ylamine and 2,2-diphenylacetic acid chloride.

Example 48

10 9H-Xanthene-9-carboxylic acid (5-ethyl-[1,3,4]oxadiazol-2-yl)-amide.

48a) 500.5 mg (1.64 mmol) (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and 186.8 mg (1.64 mmol) 5-ethyl-[1,3,4]oxadiazol-2-ylamine were suspended in 1.5 ml DMF and stirred for 6 h at 130°. The reaction mixture was allowed to cool to room temperature and 5 ml of acetone were added. After stirring for 5 min, the product was filtered, washed
15 with acetone and dried in vacuo to yield 219.5 mg of 9H-xanthene-9-carboxylic acid (5-ethyl-[1,3,4]oxadiazol-2-yl)-amide as a white solid, m.p. 256-257°C and MS: $m/e = 321.2$ (M^+)

48b) The 5-ethyl-[1,3,4]oxadiazol-2-ylamine used in the above reaction was obtained as follows:

20 To a solution of 6.3 g propionic acid hydrazide (72 mmol) in 50 ml of water was added 34 g of saturated potassium bicarbonate solution (75 mmol) and a solution of 7.7 g (72 mmol) of cyanogen bromide in 60 ml of water. The temperature rises from 22°C to 32°C and carbon dioxide evolves. After 30 min white crystals began to appear. The white suspension is stirred for 3h and left to stand overnight. The reaction mixture was
25 evaporated to dryness in vacuo. The crude product is recrystallised from 20 ml of water. The product is filtered, washed with a small amount of ice-cold water and dried in vacuo. One obtains 6.1 g (54 mmol, 75%) of 5-ethyl-[1,3,4]oxadiazol-2-ylamine as a white solid, m.p. 174-175°C and MS: $m/e = 113.1$ (M^+).

48c) The (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone used in the above
30 reaction was obtained as follows: 2.6 g (11 mmol) 9-xanthencarboxylic acid hydrazide was suspended in 2.5 ml of water. 10 ml of 2N HCl solution was added. To the thick white suspension was added 30 ml of ethanol and the suspension was heated to 65°C and then allowed to cool to room temperature. To the resulting light yellow solution was added 1.1 g (11 mmol) of acetylacetone with vigorous stirring. The temperature rises to 30°C with

formation of white crystals after about 2 min. Stirring was continued for 15 min at room temperature and a further 15 min at 0°C. The product was filtered and washed with -20°C ethanol. The crude product was recrystallised from 15 ml of ethanol to yield 2.80 g (9.2 mmol, 84%) of (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone as white
5 crystals, m.p. 114-115°C and MS: m/e = 304.1 (M⁺).

Example 49

N-(5-Ethyl-[1,3,4]oxadiazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 123-125°C and MS: m/e = 308.2 (M+H⁺) was prepared in accordance with the general method of example 48a from 1-(3,5-dimethyl-
10 pyrazol-1-yl)-2,2-diphenyl-ethanone and 5-ethyl-[1,3,4]oxadiazol-2-ylamine.

The 1-(3,5-dimethyl-pyrazol-1-yl)-2,2-diphenyl-ethanone, white solid, m.p. 91-92°C and MS: m/e = 291.2 (M+H⁺) used in the above reaction was prepared in accordance with the general method of example 48c from 2,2-diphenylacetic acid hydrazide [Chem. Zentralblatt. 100, 2414(1929)] and acetylacetone.

15

Example 50

9H-Xanthene-9-carboxylic acid (5-methyl-[1,3,4]oxadiazol-2-yl)-amide.

The title compound, white solid, m.p. 261-263°C and MS: m/e = 307.1 (M⁺) was prepared in accordance with the general method of example 44a from 5-methyl[1,3,4]oxadiazol-2-ylamine and 9-xanthene-carboxylic acid chloride.

20 The 5-methyl[1,3,4]oxadiazol-2-ylamine, white solid, MS: m/e = 99 (M⁺) used in the above reaction was prepared in accordance with the general method of example 48b from acetic acid hydrazide and cyanogen bromide.

Example 51

N-(5-Methyl-[1,3,4]oxadiazol-2-yl)-2,2-diphenyl-acetamide.

25 The title compound, white solid, m.p. 160-161°C and MS: m/e = 293.1 (M⁺) was prepared in accordance with the general method of example 44a from 5-methyl[1,3,4]oxadiazol-2-ylamine and 2,2-diphenylacetic acid chloride.

Example 52

9H-Xanthene-9-carboxylic acid (5-methoxymethyl-[1,3,4]oxadiazol-2-yl)-amide.

30 The title compound, white solid, m.p. 233-234°C and MS: m/e = 337.1 (M+H⁺) was prepared in accordance with the general method of example 48a from (3,5-

dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and 5-methoxymethyl-[1,3,4]oxadiazol-2-ylamine.

The 5-methoxymethyl-[1,3,4]oxadiazol-2-ylamine, white solid, m.p. 113-114°C and MS: m/e = 129.2 (M^+) used in the above reaction was prepared in accordance with the general method of example 48b from methoxyacetic acid hydrazide [J.Org.Chem.USSR, 6(1), 93(1970)] and cyanogen bromide.

Example 53

N-(5-Ethyl-[1,3,4]oxadiazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 138-140°C and MS: m/e = 324.3 ($M+H^+$) was prepared in accordance with the general method of example 44a from 2,2-diphenylacetic acid chloride and 5-methoxymethyl-[1,3,4]oxadiazol-2-ylamine.

Example 54

9H-Xanthene-9-carboxylic acid [5-(2-methoxy-ethyl)-[1,3,4]oxadiazol-2-yl]-amide.

The title compound, white solid, m.p. 204°C and MS: m/e = 351.1 ($M+H^+$) was prepared in accordance with the general method of example 44a from (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and [5-(2-methoxy-ethyl)-[1,3,4]oxadiazol-2-yl]-amine.

The [5-(2-methoxy-ethyl)-[1,3,4]oxadiazol-2-yl]-amine, white solid, m.p. 105-106°C and MS: m/e = 143.1 (M^+) used in the above reaction was prepared in accordance with the general method of example 48b from 3-methoxypropionic acid hydrazide [US 3441606] and cyanogen bromide.

Example 55

N-[5-(2-Methoxy-ethyl)-[1,3,4]oxadiazol-2-yl]-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 114-115°C and MS: m/e = 338.2 ($M+H^+$) was prepared in accordance with the general method of example 44a from 2,2-diphenylacetic acid chloride and [5-(2-methoxy-ethyl)-[1,3,4]oxadiazol-2-yl]-amine.

Example 56

9H-Xanthene-9-carboxylic acid (5-cyclopropyl-[1,3,4]oxadiazol-2-yl)-amide.

The title compound, white solid, m.p. 246-248°C and MS: m/e = 333.1 ($M+H^+$) was prepared in accordance with the general method of example 48a from (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and 5-cyclopropyl-[1,3,4]oxadiazol-2-ylamine [J.Med.Pharm.Chem. 5, 617(1962)].

Example 57N-(5-Cyclopropyl-[1,3,4]oxadiazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 159-160°C and MS: m/e = 320.3 (M+H⁺) was prepared in accordance with the general method of example 44a from 2,2-diphenylacetic acid chloride and 5-cyclopropyl-[1,3,4]oxadiazol-2-ylamine.

Example 589H-Xanthene-9-carboxylic acid (5-cyclopropylmethyl-[1,3,4]oxadiazol-2-yl)-amide.

The title compound, white solid, m.p. 234-236°C and MS: m/e = 347.1 (M+H⁺) was prepared in accordance with the general method of example 48a from (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and 5-cyclopropylmethyl-[1,3,4]oxadiazol-2-ylamine.

The 5-cyclopropylmethyl-[1,3,4]oxadiazol-2-ylamine, white solid, m.p. 140-141°C and MS: m/e = 139 (M⁺) used in the above reaction was prepared in accordance with the general method of example 48b from cyclopropanecarboxylic acid hydrazide [J.Chem.Soc.Perkin Trans.2,1844(1974)] and cyanogen bromide.

Example 59N-(5-Cyclopropylmethyl-[1,3,4]oxadiazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 158-159°C and MS: m/e = 334.3 (M+H⁺) was prepared in accordance with the general method of example 44a from 2,2-diphenylacetic acid chloride and 5-cyclopropylmethyl-[1,3,4]oxadiazol-2-ylamine.

Example 609H-Xanthene-9-carboxylic acid (5-trifluoromethyl-[1,3,4]oxadiazol-2-yl)-amide.

The title compound, white solid, m.p. 220-223°C(decomp.), and MS: m/e = 362.2 (M+H⁺) was prepared in accordance with the general method of example 48a from (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and 5-trifluoromethyl-[1,3,4]oxadiazol-2-ylamine [US 2883391].

Example 61N-(5-Trifluoromethyl-[1,3,4]oxadiazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 149-150°C and MS: $m/e = 347.2$ (M^+) was prepared in accordance with the general method of example 44a from 5-trifluoromethyl[1,3,4]oxadiazol-2-ylamine and 2,2-diphenylacetic acid chloride.

Example 62

5 9H-Xanthene-9-carboxylic acid (5-ethyl-oxazol-2-yl)-amide.

The title compound, white solid, m.p. 212-213°C and MS: $m/e = 320.1$ (M^+) was prepared in accordance with the general method of example 44a from 5-ethyl-oxazol-2-ylamine [Ber. 95, 2419(1962)] and 9-xanthene-carboxylic acid chloride.

Example 63

10 N-(5-Ethyl-oxazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 148-149°C and MS: $m/e = 307.3$ ($M+H^+$) was prepared in accordance with the general method of example 44a from 5-ethyl-oxazol-2-ylamine and 2,2-diphenylacetic acid chloride.

Example 64

15 9H-Xanthene-9-carboxylic acid (5-methyl-oxazol-2-yl)-amide.

The title compound, white solid, m.p. 217-220°C and MS: $m/e = 306.1$ (M^+) was prepared in accordance with the general method of example 44a from 5-methyl-oxazol-2-ylamine [Ber. 95, 2419(1962)] and 9-xanthene-carboxylic acid chloride.

Example 65

20 N-(5-Methyl-oxazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, off-white solid, m.p. 166-168°C and MS: $m/e = 292.2$ (M^+) was prepared in accordance with the general method of example 44a from 5-methyl-oxazol-2-ylamine and 2,2-diphenylacetic acid chloride.

Example 66

25 9H-Xanthene-9-carboxylic acid (5-propyl-oxazol-2-yl)-amide.

66a) The title compound, white solid, m.p. 203-205°C and MS: $m/e = 334.1$ (M^+) was prepared in accordance with the general method of example 44a from 5-propyl-oxazol-2-ylamine [Ber. 95, 2419(1962)] and 9-xanthene-carboxylic acid chloride.

66b) The 5-propyl-[1,3,4]oxadiazol-2-ylamine used in the above reaction was obtained as follows: 21.8 g (0.132 mol) of 2-bromobutyraldehyde [Chem.Ber., 70,1898(1937)] was
30 dissolved in 67.5 ml of a 4:3 mixture of DMF and water. Urea, 8.77 g (0.145 mol) was added with stirring. The clear colorless solution was stirred for 16h at 105°C. The resulting

light yellow solution is cooled to 0°C and 10 ml of 45% Sodium hydroxide solution was added. The solution turns dark yellow (pH 12). 100 ml of brine is added and the solution is extracted five times with 100 ml of a 9:1 mixture of methylene chloride and methanol. The combined organic phases were concentrated to yield 15.62 g of a reddish brown oil which
5 was purified by flash chromatography on silicagel with a 9:1 mixture of methylene chloride and methanol as eluent. One obtains 6.2 g (0.049 mol, 37%) of 5-5-propyl-oxazol-2-ylamine as a yellow oil which was directly used without further purification, MS: m/e = 126.1 (M^+).

Example 67

10 2,2-Diphenyl-N-(5-propyl-oxazol-2-yl)-acetamide.

The title compound, white solid, m.p. 122°C and MS: m/e = 320.2 (M^+) was prepared in accordance with the general method of example 44a from 5-propyl-oxazol-2-ylamine and 2,2-diphenylacetic acid chloride.

Example 68

15 9H-Xanthene-9-carboxylic acid (4-methyl-oxazol-2-yl)-amide.

The title compound, light yellow solid, m.p. 219-222°C and MS: m/e = 306.1 (M^+) was prepared in accordance with the general method of example 48a from (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and 5-methyl-oxazol-2-ylamine [DE 2459380].

20 Example 69

N-(4-Methyl-oxazol-2-yl)-2,2-diphenyl-acetamide.

The title compound, white solid, m.p. 209-211°C and MS: m/e = 306.1 (M^+) was prepared in accordance with the general method of example 48a from (3,5-dimethylpyrazol-1-yl)-(9H-xanthen-9-yl)-methanone and 5-methyl-oxazol-2-ylamine.

25 Example 70

N-(3-Methyl-[1,2,4]oxadiazol-5-yl)-2,2-diphenyl-acetamide

The title compound, white solid, m.p. 215°C and MS: m/e = 293 (M^+) was prepared in accordance with the general method of example 44a from 3-methyl-[1,2,4]oxadiazol-5-ylamine (Helv. Chim. Acta, 49(1966), 1430-1432) and 2,2-diphenylacetic acid chloride.

30 Example 71

9H-Xanthene-9-carboxylic acid (3-methyl-[1,2,4]oxadiazol-5-yl)-amide

The title compound, white solid, m.p. 208°C and MS: $m/e = 307$ (M^+) was prepared in accordance with the general method of example 44a from 3-methyl-[1,2,4]oxadiazol-5-ylamine and 9H-xanthene-carboxylic acid chloride.

Example 72

5 N-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-2,2-diphenyl-acetamide

The title compound, white solid, m.p. 163°C and MS: $m/e = 219$ (M^+) was prepared in accordance with the general method of example 44a from 3-cyclopropyl-[1,2,4]oxadiazol-5-ylamine (Helv. Chim. Acta, 49(1966), 1430-1432) and 2,2-diphenylacetic acid chloride.

Example 73

10 9H-Xanthene-9-carboxylic acid (3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-amide

The title compound, white solid, m.p. 275°C and MS: $m/e = 333$ (M^+) was prepared in accordance with the general method of example 44a from 3-cyclopropyl-[1,2,4]oxadiazol-5-ylamine and 9H-xanthene-carboxylic acid chloride.

Example 74

15 N-(5-Methyl-[1,2,4]oxadiazol-3-yl)-2,2-diphenyl-acetamide

The title compound, white solid, m.p. 153°C and MS: $m/e = 293$ (M^+) was prepared in accordance with the general method of example 44a from 5-methyl-[1,2,4]oxadiazol-3-ylamine (EP 413545) and 2,2-diphenylacetic acid chloride.

Example 75

20 9H-Xanthene-9-carboxylic acid (5-methyl-[1,2,4]oxadiazol-3-yl)-amide

The title compound, white solid, m.p. 186°C and MS: $m/e = 307$ (M^+) was prepared in accordance with the general method of example 44a from 5-methyl-[1,2,4]oxadiazol-3-ylamine and 9H-xanthene-carboxylic acid chloride.

- 32 -

Example A

Tablets of the following composition are produced in a conventional manner:

5		<u>mg/Tablet</u>
	Active ingredient	100
	Powdered. lactose	95
	White corn starch	35
	Polyvinylpyrrolidone	8
10	Na carboxymethylstarch	10
	Magnesium stearate	<u>2</u>
	Tablet weight	250

Example B

15 Tablets of the following composition are produced in a conventional manner:

		<u>mg/Tablet</u>
	Active ingredient	200
	Powdered. lactose	100
20	White corn starch	64
	Polyvinylpyrrolidone	12
	Na carboxymethylstarch	20
	Magnesium stearate	<u>4</u>
	Tablet weight	400

Example C

Capsules of the following composition are produced:


	<u>mg/Capsule</u>
5 Active ingredient	50
Crystalline lactose	60
Microcrystalline cellulose	34
Talc	5
Magnesium stearate	<u>1</u>
10 Capsule fill weight	150

The active ingredient having a suitable particle size, the crystalline lactose and the microcrystalline cellulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed. The final mixture is filled into hard
15 gelatine capsules of suitable size.

- 34 -


Claims

1. Compounds of the general formula



wherein


- 5 R^1 signifies hydrogen or lower alkyl;
 $R^2, R^{2'}$ signify, independently from each other, hydrogen, lower alkyl, lower alkoxy,
 halogen or trifluoromethyl;
 X signifies O, S or two hydrogen atoms not forming a bridge;
 A^1/A^2 signify, independently from each other, phenyl or a 6-membered heterocycle
 10 containing 1 or 2 nitrogen atoms;
 B is a group of formula



wherein

- R^3 signifies lower alkyl, lower alkenyl, lower alkynyl, benzyl, lower alkyl-
 15 cycloalkyl, lower alkyl-cyano, lower alkyl-pyridinyl, lower alkyl-lower alkoxy-phenyl,
 lower alkyl-phenyl, which is optionally substituted by lower alkoxy, or phenyl, which
 is optionally substituted by lower alkoxy, or lower alkyl-thienyl, cycloalkyl, lower
 alkyl-trifluoromethyl or lower alkyl-morpholinyl,
 Y signifies -O-, -S- or a bond;
 20 Z signifies -O- or -S-;
 or B is a 5-membered heterocyclic group of formulas

- 35 -




wherein


R^4 and R^5 signifies hydrogen, lower alkyl, lower alkoxy, cyclohexyl, lower alkyl-cyclohexyl or trifluoromethyl, with the proviso that at least one of R^4 or R^5 has to be

as well as their pharmaceutically acceptable salts.

2. Compounds of formula IA in accordance with claim 1,




wherein B is a group of formula



and the remaining substituents are defined in claim 1.


3. Compounds of formula IB in accordance with claim 1,

- 36 -



wherein

B is a 5-membered heterocyclic group of formulas



5 and the remaining substituents are as defined in claim 1.

4. Compounds of formula IA in accordance with claim 2, in which A signifies phenyl, X signifies 2 hydrogen atoms not forming a bridge and Z is -O-.

5. Compounds in accordance with claim 4, which compounds are

diphenylacetyl-carbamic acid butyl ester,
 10 diphenylacetyl-carbamic acid ethyl ester or
 diphenylacetyl-carbamic acid pent-4-ynyl ester

6. Compounds of formula IA in accordance with claim 2, , in which A signifies phenyl, X signifies -O- or -S- and Z is -O-.

7. Compounds of formula IA in accordance with claim 6, which compounds are

15 (9H-xanthene-9-carbonyl)-carbamic acid ethyl ester,
 (9H-xanthene-9-carbonyl)-carbamic acid butyl ester or
 (9H-thioxanthene-9-carbonyl)-carbamic acid butyl ester.

8. Compounds of formula IB in accordance with claim 3, in which A signifies phenyl, X signifies 2 hydrogen atoms not forming a bridge and Z is -O-.

9. Compounds of formula IB in accordance with claim 8, which compounds are

- N-(5-ethyl-oxazol-2-yl)-2,2-diphenyl-acetamide,
N-(5-methyl-oxazol-2-yl)-2,2-diphenyl-acetamide,
2,2-diphenyl-N-(5-propyl-[1,3,4]oxadiazol-2-yl)-acetamide,
5 N-[5-(2-methoxy-ethyl)-[1,3,4]oxadiazol-2-yl]-2,2-diphenyl-acetamide,
N-(3-methyl-[1,2,4]oxadiazol-5-yl)-2,2-diphenyl-acetamide,
N-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-2,2-diphenyl-acetamide or
N-(5-methyl-[1,2,4]oxadiazol-3-yl)-2,2-diphenyl-acetamide

10. Compounds of formula IB in accordance with claim 3, in which A signifies
10 phenyl, X signifies -O- and Z is -O-.

11. Compounds of formula IB in accordance with claim 10, which compounds are

- 9H-xanthene-9-carboxylic acid oxazol-2-yl-amide,
9H-xanthene-9-carboxylic acid (5-propyl-[1,3,4]oxadiazol-2-yl)-amide,
9H-xanthene-9-carboxylic acid (5-ethyl-oxazol-2-yl)-amide,
15 9H-xanthene-9-carboxylic acid (5-methyl-oxazol-2-yl)-amide,
9H-xanthene-9-carboxylic acid (5-propyl-oxazol-2-yl)-amide,
9H-xanthene-9-carboxylic acid (5-ethyl-[1,3,4]oxadiazol-2-yl)-amide,
9H-xanthene-9-carboxylic acid (5-cyclopropylmethyl-[1,3,4]oxadiazol-2-yl)-amide,
9H-xanthene-9-carboxylic acid (4-methyl-oxazol-2-yl)-amide,
20 9H-xanthene-9-carboxylic acid (3-methyl-[1,2,4]oxadiazol-5-yl)-amide,
9H-Xanthene-9-carboxylic acid (5-trifluoromethyl-[1,3,4]oxadiazol-2-yl)-amide,
9H-Xanthene-9-carboxylic acid (5-methoxymethyl-[1,3,4]oxadiazol-2-yl)-amide,
9H-xanthene-9-carboxylic acid (3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-amide or
9H-xanthene-9-carboxylic acid (5-methyl-[1,2,4]oxadiazol-3-yl)-amide.

25

12.A medicament comprising a compound according to any one of claims 1-11
as well as pharmaceutically acceptable salts thereof and pharmaceutically acceptable
excipients.

13. A medicament in accordance with claim 12 for the control or prevention of
30 acute and/or chronic neurological disorders such as restricted brain function caused by
bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head
injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycaemia, Alzheimer's disease,
Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, cognitive
disorders, memory deficits, schizophrenia, idiopathic parkinsonism or parkinsonism
35 caused by medicaments as well as conditions which lead to glutamate deficiency functions,

- 38 -

such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, acute and chronic pain, dyskinesia and depression.

14. The use of compounds in accordance with anyone of claims 1-11 as well as
5 pharmaceutically acceptable salts thereof in the control or prevention of illnesses


15. The use of compounds of formula I in accordance with anyone of claims 1-11 for the production of medicaments, containing compounds of formula I for the treatment of diseases as claimed in claim 13.

16. Compounds in accordance with claims 1-11 as well as pharmaceutically
10 acceptable salts thereof for the control or prevention of acute and/or chronic neurological disorders.


17. A process for the manufacture of compounds according to any one of claim 1-11 as well as of pharmaceutically acceptable salts thereof, which process comprises

b) reacting a compound of the formula

15




with a compound of the formula




to a compound of formula

- 39 -




wherein the substituents have the significances given in claim 1, or
b) reacting a compound of formula




5

with a compound of the formula



to a compound of formula




10 in which G is a suitable leaving group and the other substituents have the significances


- 40 -

given in claim 1,

c) or reacting a compound of formula




with a compound of the formula



5


to a compound of formula



wherein the substituents have the significances given in claim 1,


or

10 d) reacting a compound of formula




- 41 -

with a compound of the formula




to a compound of formula




5 wherein the substituents have the significances set forth in claim 1, or

e) reacting a compound of formula




with a heterocyclic compound of formula




10 to give a compound of formula

- 42 -



wherein B is a 5-membered heterocycle of the formulas



and wherein G is a leaving group and the remaining substituents have the significances
5 given in claim 1,

and, if desired,

converting a functional group in a compound of formula I into another functional group
and, if desired,

converting a compound of formula I into a pharmaceutically acceptable salt.

10 18. Compounds in accordance with claims 1-11, when manufactured according to a process in accordance with claim 17.

19. The invention as herein described.

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/EP 00/03556

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C271/64 C07D311/84 C07D335/14 C07D263/48 C07D271/113
C07D271/07 C07D413/12 C07D213/30 C07D333/16 C07C333/10
C07D213/61 C07C233/90 C07C233/91 C07D295/088 A61K31/325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BEHRINGER H ET AL: "Darstellung von Diaryl(3-phenyl-1,2,4-triazol-5-yl) methanolen" JUSTUS LIEBIGS ANNALEN DER CHEMIE, no. 7/8, 24 September 1975 (1975-09-24), pages 1264-71, XP002145480 pages 1265 and 1267, compound 4	1, 17-19
X	HOHENLOHE-OEHRINGEN K: "Reaktionen des 5,5-Diphenyl-4-hydroxy-1,2,3-triazols" MONATSCHEFTE FÜR CHEMIE, vol. 89, no. 4/5, 25 October 1958 (1958-10-25), pages 588-96, XP002145481 pages 593 and 596, compound XVI	1, 2, 4, 17-19
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 August 2000

Date of mailing of the international search report

19/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

Int. .ional Application No

PCT/EP 00/03556

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/352 A61K31/382 A61K31/421 A61K31/422 A61K31/4245
A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CASAGRANDE C ET AL: "Synthesis and antiarrhythmic activity of 5,5-disubstituted-3-aminoalkylhydantoins and some heterocyclic and noncyclic analogues" IL FARMACO - EDIZIONE SCIENTIFICA, vol. 29, no. 10, October 1974 (1974-10), pages 757-85, XP002145482 pages 769, 783 and 784, compounds LXVIII and LXXI --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 August 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/EP 00/03556

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 62, no. 3, 1 February 1965 (1965-02-01) Columbus, Ohio, US; abstract no. 2742g, XP002145483 abstract & JP 39 012921 B (DAINIPPON PHARMACEUTICAL CO., LTD.) 8 July 1964 (1964-07-08)	1,2,4, 12,13, 16-19
A	EP 0 849 263 A (ELI LILLY AND COMPANY LIMITED) 24 June 1998 (1998-06-24) the whole document	1,13
A	TOMS N J ET AL: "Latest eruptions in metabotropic glutamate receptors" TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 17, no. 12, 1 December 1996 (1996-12-01), pages 429-435, XP004063289 ISSN: 0165-6147 the whole document	1,13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/03556

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 39012921 B		NONE	
EP 849263 A	24-06-1998	CA 2224835 A	17-06-1998
		JP 10182629 A	07-07-1998
		US 5891899 A	06-04-1999